Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 4/20 | 0.37 |
| ▸ | NQO1 | P15559 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | TOP2A | P11388 | 2/20 | 0.36 |
| ▸ | NSD2 | O96028 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL105984 | 1.00 | IDO1 (0.37) | IDO1NQO2NQO1MEN1USP2 | |
| Hydrochloric Acid SCHEMBL1650422 | 0.98 | NQO2 (0.36) | IDO1NQO2NQO1MEN1USP2 | |
| SCHEMBL8543978 | 0.94 | IDO1 (0.35) | IDO1NQO2NQO1MEN1USP2 | |
| SCHEMBL5082535 | 0.92 | IDO1 (0.37) | IDO1NQO2NQO1MEN1USP2 | |
| SCHEMBL8542166 | 0.92 | MEN1 (0.44) | NQO2NQO1MEN1USP2LMNA | |
| SCHEMBL8546191 | 0.91 | IDO1 (0.37) | IDO1NQO2NQO1 | |
| SCHEMBL8545959 | 0.90 | NQO2 (0.38) | IDO1NQO2NQO1MEN1USP2 | |
| SCHEMBL8543922 | 0.89 | MEN1 (0.37) | NQO2NQO1MEN1USP2LMNA | |
| SCHEMBL8543902 | 0.87 | IDO1 (0.35) | IDO1NQO2NQO1 | |
| SCHEMBL8547450 | 0.86 | NQO1 (0.43) | NQO2NQO1PAX8SMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2026107349-A1 | HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES | ANTARES THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| US-12539304-B2 | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor | PFIZER INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| EP-4673747-A1 | MEANS AND METHODS FOR DIAGNOSING CANCER AND/OR AN ACUTE INFLAMMATORY DISEASE | CARCIMUN BIOTECH GmbH (DE) | 2026-01-07 | — | — | EP | disclosed |
| US-12502368-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2025-12-23 | — | — | US | disclosed |
| WO-2025244963-A1 | ECTEINASCIDIN DERIVATIVES AND METHODS OF USE THEREOF AS ANTITUMOR AGENTS | MERCK SHARP & DOHME LLC (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4646411-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20220081445-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | MINGHUI PHARMACEUTICAL SHANGHAI LTD (CN) | 2022-03-17 | — | — | US | disclosed |
| CN-114177308-A | anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-20220072204-A1 | Platelet-Derived Growth Factor Compositions and Methods of Use Thereof | BIOMIMETIC THERAPEUTICS LLC (US) | 2022-03-10 | — | — | US | disclosed |
| US-20220072001-A1 | G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2022-03-10 | — | — | US | disclosed |
| US-11253515-B2 | Pharmaceutical compositions and dosage forms | IGNYTA, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11247983-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
| US-11248028-B2 | Desmoglein 2 (DSG2) binding proteins and uses therefor | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-108289922-B | Therapeutic methods and compositions for treating non-small cell lung cancer | 友杏生技医药股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-11242407-B2 | High-affinity anti-MERTK antibodies and uses thereof | INSPIRNA, INC. (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CTRB1, CTRB2, CPN1 | IDO1 2530/4885NQO2 2036/4885NQO1 3057/4885 |
| US-12539304-B2 | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor | CDK4, CDK2, CDK6 | IDO1 3305/4885NQO2 2137/4885NQO1 3761/4885 |
| US-11253515-B2 | Pharmaceutical compositions and dosage forms | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | IDO1 1205/4885NQO2 132/4885NQO1 33/4885 |
| US-12502368-B2 | Treatment and diagnosis of melanoma | EYA3, BRAF, CD99 | IDO1 1259/4885NQO2 1452/4885NQO1 1005/4885 |
| US-20220081445-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | ABL1, BTK, LYN | IDO1 3195/4885NQO2 1353/4885NQO1 4567/4885 |
| US-20220072001-A1 | G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES | GCGR, GPR3, GPR132 | IDO1 914/4885NQO2 1953/4885NQO1 4151/4885 |
| US-11247983-B2 | Compounds and methods for inhibiting JAK | JAK2, JAK3, JAK1 | IDO1 936/4885NQO2 2700/4885NQO1 3879/4885 |
| US-12545684-B2 | CDK2 inhibitors | CDK2, CDK4, CDK1 | IDO1 3071/4885NQO2 976/4885NQO1 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.